SCS Capital Management LLC Takes Position in Boston Scientific Corporation $BSX

Key Points

• SCS Capital Management LLC has acquired a new stake in Boston Scientific, purchasing 2,473 shares valued at approximately $249,000.
• Analysts have recently upgraded Boston Scientific's stock ratings, with UBS raising its price target to $135.00 and three investment analysts giving it a "Strong Buy" rating.
• Boston Scientific reported a significant revenue increase of 22.8% year-over-year, with quarterly earnings per share of $0.75, exceeding analyst expectations.

SCS Capital Management LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,473 shares of the medical equipment provider's stock, valued at approximately $249,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. 1248 Management LLC bought a new position in shares of Boston Scientific during the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the 1st quarter valued at approximately $27,000. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $25,000. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific during the 4th quarter valued at $26,000. Finally, Ameriflex Group Inc. purchased a new stake in Boston Scientific during the 4th quarter valued at $31,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BSX shares. UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Stock Performance

BSX stock opened at $102.71 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business's fifty day simple moving average is $104.86 and its two-hundred day simple moving average is $102.26. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The firm has a market cap of $152.19 billion, a price-to-earnings ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm posted $0.62 earnings per share. The business's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $18,397,457. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.